相关实验视频

Updated: May 13, 2026

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

Published on: May 16, 2012

识别MTHFD1和LGALS4作为前列腺癌中潜在的治疗点,通过多奥米克门德尔随机化分析

Huan Han¹, Hanwen Su¹, Zhihua Lv¹

¹Department of Clinical Laboratory, Institute of Translational Medicine, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, China.

|January 25, 2025

概括

这项研究确定了MTHFD1和LGALS4作为前列腺腺癌 (PRAD) 的潜在治疗点. 需要进一步的研究来证实它们在预防PRAD方面的有效性.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
药理学药理学是指药理学的学科.

背景情况:

前列腺癌是全球男性癌症死亡的主要原因之一.
目前的治疗方法包括手术,放射治疗和激素治疗.
改善药物标对于更好的前列腺癌诊断和治疗至关重要.

研究的目的:

查前列腺腺癌 (PRAD) 风险的新药标.
用多omics数据和临床信息验证候选基因.
预测潜在的向药物对已识别的候选基因.

主要方法:

集成的eQTL和pQTL数据与孟德尔随机化 (MR) 分析.
利用TCGA数据进行基因表达,生存和免疫微环境分析.
采用TIDE,单细胞RNA测序和药物数据库用于验证和药物预测.

主要成果:

MTHFD1和LGALS4被确定为PRAD的有希望的治疗点.
LGALS4与免疫疗法耐药性相关,而MTHFD1与生存率低下有关.
目前没有批准的药物专门针对MTHFD1或LGALS4.

结论:

MTHFD1和LGALS4显示出作为PRAD的预防性目标的潜力.
需要进一步的实验验证,以评估它们的临床实用性和有效性.
这项研究强调了用于识别新型癌症点的多omics方法.

关键词:

在LGALS4中在MTHFD1中.门德尔的随机化药物目标是药物目标.前列腺癌是前列腺癌.

更多相关视频

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

相关概念视频

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...